Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of glofitamab (RO7082859) in relapsed/refractory B-cell non-Hodgkin lymphoma
jRCT2080225077Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glofitamab in non-Hodgkin lymphoma (NHL), sponsored by Chugai Pharmaceutical Co., Ltd. Started Feb 2020; status: completed.
02
Drugs
glofitamab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2080225077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225077.